Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021 Thumbnail Image Read more about Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021
X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia Thumbnail Image Read more about X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to Treat Patients with Double-Mutation Waldenström’s Macroglobulinemia
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting Thumbnail Image Read more about Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting Thumbnail Image Read more about Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology Annual Meeting
Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd ASH Annual Meeting Thumbnail Image Read more about Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd ASH Annual Meeting
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis Thumbnail Image Read more about MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413 Thumbnail Image Read more about Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for IRAKIMiD Degrader, KT-413
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study for CD30-positive Lymphomas Thumbnail Image Read more about Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study for CD30-positive Lymphomas
Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors Thumbnail Image Read more about Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors
Kymera Therapeutics Receives IND Clearance for KT-333, a STAT3 Degrader, for the Treatment of Hematologic and Solid Malignancies Thumbnail Image Read more about Kymera Therapeutics Receives IND Clearance for KT-333, a STAT3 Degrader, for the Treatment of Hematologic and Solid Malignancies
